Seattle Genetics Says Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS in CD30-Expressing Cutaneous T-Cell Lymphoma at #ASH2017 Indicate Primary, Secondary Endpoints per Investigator Better than Previously Reported